CORAL SPRINGS, Fla., April 28, 2010 (GLOBE NEWSWIRE) -- CyGene Laboratories Inc. (Pink Sheets:CYGE) today announced that it has formed an international sales organization that is tasked with rapidly expanding the number of sales channels for the company's multiple DNA test panels, which are marketed primarily to consumers.
Heading this new organization is Rodolfo E. Gonzalez who has been named Director of Global Development. He will be based out of the company's Coral Springs corporate headquarters. Mr. Gonzalez was formerly the Executive Vice President of Sales and Marketing (Latin America) for a multi-national publicly-traded Fortune 500 company. He has extensive knowledge and experience in all aspects of channel development and sales management.
"We are pleased to have someone like Rodolfo join our organization," said Martin Munzer, the CEO of CyGene. "We have high expectations based on his background and proven track record of building revenues in high growth industries."
Mr. Gonzalez said, "CyGene is uniquely positioned to bring the diagnostic and predictive benefits of genetic testing to the general population. I'm very excited to be a part of the CyGene team."
Mr. Gonzalez will lead the company's effort to rapidly expand its sales channels globally and build a world class sales organization. Mr. Gonzalez has indicated that he expects to work closely with CyGene's existing channel partners.
About CyGene Laboratories, Inc.
CyGene Laboratories, Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available.
For more information about CyGene Laboratories and its products, visit the Company's Web site at http://www.CyGeneDirect.com/.
The CyGene Laboratories Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6480
Forward-Looking Statements:
The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.